Chromosome 17 alterations identify goodrisk and poor-risk tumors independently of clinical factors in medulloblastomaCitation formats

  • External authors:
  • Martin G. McCabe
  • L. Magnus Bäcklund
  • Hui Sun Leong
  • Koichi Ichimura
  • V. Peter Collins

Standard

Chromosome 17 alterations identify goodrisk and poor-risk tumors independently of clinical factors in medulloblastoma. / Mccabe, Martin; McCabe, Martin G.; Bäcklund, L. Magnus; Leong, Hui Sun; Ichimura, Koichi; Collins, V. Peter.

In: Neuro-Oncology, Vol. 13, No. 4, 04.2011, p. 376-383.

Research output: Contribution to journalArticle

Harvard

Mccabe, M, McCabe, MG, Bäcklund, LM, Leong, HS, Ichimura, K & Collins, VP 2011, 'Chromosome 17 alterations identify goodrisk and poor-risk tumors independently of clinical factors in medulloblastoma', Neuro-Oncology, vol. 13, no. 4, pp. 376-383. https://doi.org/10.1093/neuonc/noq192

APA

Mccabe, M., McCabe, M. G., Bäcklund, L. M., Leong, H. S., Ichimura, K., & Collins, V. P. (2011). Chromosome 17 alterations identify goodrisk and poor-risk tumors independently of clinical factors in medulloblastoma. Neuro-Oncology, 13(4), 376-383. https://doi.org/10.1093/neuonc/noq192

Vancouver

Author

Mccabe, Martin ; McCabe, Martin G. ; Bäcklund, L. Magnus ; Leong, Hui Sun ; Ichimura, Koichi ; Collins, V. Peter. / Chromosome 17 alterations identify goodrisk and poor-risk tumors independently of clinical factors in medulloblastoma. In: Neuro-Oncology. 2011 ; Vol. 13, No. 4. pp. 376-383.

Bibtex

@article{1313c02e07ae4ad6b4feaf434eceaa30,
title = "Chromosome 17 alterations identify goodrisk and poor-risk tumors independently of clinical factors in medulloblastoma",
abstract = "Current risk stratification schemas for medulloblastoma, based on combinations of clinical variables and histotype, fail to accurately identify particularly good-and poor-risk tumors. Attempts have been made to improve discriminatory power by combining clinical variables with cytogenetic data. We report here a pooled analysis of all previous reports of chromosomal copy number related to survival data in medulloblastoma. We collated data from previous reports that explicitly quoted survival data and chromosomal copy number in medulloblastoma. We analyzed the relative prognostic significance of currently used clinical risk stratifiers and the chromosomal aberrations previously reported to correlate with survival. In the pooled dataset metastatic disease, incomplete tumor resection and severe anaplasia were associated with poor outcome, while young age at presentation was not prognostically significant. Of the chromosomal variables studied, isolated 17p loss and gain of lq correlated with poor survival. Gain of 17q without associated loss of 17p showed a trend to improved outcome. The most commonly reported alteration, isodicentric chromosome 17, was not prognostically significant. Sequential multivariate models identified isolated 17 p/loss, isolated 17q gain, and lq gain as independent prognostic factors. In a historical dataset, we have identified isolated 17p loss as a marker of poor outcome and 17q gain as a novel putative marker of good prognosis. Biological markers of poor-risk and good-risk tumors will be critical in stratifying treatment in future trials. Our findings should be prospectively validated independently in future clinical studies. {\circledC} The Author(s) 2011.",
keywords = "17 q gain, 17p loss, Cytogenetic, I(17q), Isochromosome, Lq gain, Medulloblastoma, Monosomy 6, Risk stratification, Survival",
author = "Martin Mccabe and McCabe, {Martin G.} and B{\"a}cklund, {L. Magnus} and Leong, {Hui Sun} and Koichi Ichimura and Collins, {V. Peter}",
year = "2011",
month = "4",
doi = "10.1093/neuonc/noq192",
language = "English",
volume = "13",
pages = "376--383",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Chromosome 17 alterations identify goodrisk and poor-risk tumors independently of clinical factors in medulloblastoma

AU - Mccabe, Martin

AU - McCabe, Martin G.

AU - Bäcklund, L. Magnus

AU - Leong, Hui Sun

AU - Ichimura, Koichi

AU - Collins, V. Peter

PY - 2011/4

Y1 - 2011/4

N2 - Current risk stratification schemas for medulloblastoma, based on combinations of clinical variables and histotype, fail to accurately identify particularly good-and poor-risk tumors. Attempts have been made to improve discriminatory power by combining clinical variables with cytogenetic data. We report here a pooled analysis of all previous reports of chromosomal copy number related to survival data in medulloblastoma. We collated data from previous reports that explicitly quoted survival data and chromosomal copy number in medulloblastoma. We analyzed the relative prognostic significance of currently used clinical risk stratifiers and the chromosomal aberrations previously reported to correlate with survival. In the pooled dataset metastatic disease, incomplete tumor resection and severe anaplasia were associated with poor outcome, while young age at presentation was not prognostically significant. Of the chromosomal variables studied, isolated 17p loss and gain of lq correlated with poor survival. Gain of 17q without associated loss of 17p showed a trend to improved outcome. The most commonly reported alteration, isodicentric chromosome 17, was not prognostically significant. Sequential multivariate models identified isolated 17 p/loss, isolated 17q gain, and lq gain as independent prognostic factors. In a historical dataset, we have identified isolated 17p loss as a marker of poor outcome and 17q gain as a novel putative marker of good prognosis. Biological markers of poor-risk and good-risk tumors will be critical in stratifying treatment in future trials. Our findings should be prospectively validated independently in future clinical studies. © The Author(s) 2011.

AB - Current risk stratification schemas for medulloblastoma, based on combinations of clinical variables and histotype, fail to accurately identify particularly good-and poor-risk tumors. Attempts have been made to improve discriminatory power by combining clinical variables with cytogenetic data. We report here a pooled analysis of all previous reports of chromosomal copy number related to survival data in medulloblastoma. We collated data from previous reports that explicitly quoted survival data and chromosomal copy number in medulloblastoma. We analyzed the relative prognostic significance of currently used clinical risk stratifiers and the chromosomal aberrations previously reported to correlate with survival. In the pooled dataset metastatic disease, incomplete tumor resection and severe anaplasia were associated with poor outcome, while young age at presentation was not prognostically significant. Of the chromosomal variables studied, isolated 17p loss and gain of lq correlated with poor survival. Gain of 17q without associated loss of 17p showed a trend to improved outcome. The most commonly reported alteration, isodicentric chromosome 17, was not prognostically significant. Sequential multivariate models identified isolated 17 p/loss, isolated 17q gain, and lq gain as independent prognostic factors. In a historical dataset, we have identified isolated 17p loss as a marker of poor outcome and 17q gain as a novel putative marker of good prognosis. Biological markers of poor-risk and good-risk tumors will be critical in stratifying treatment in future trials. Our findings should be prospectively validated independently in future clinical studies. © The Author(s) 2011.

KW - 17 q gain

KW - 17p loss

KW - Cytogenetic

KW - I(17q)

KW - Isochromosome

KW - Lq gain

KW - Medulloblastoma

KW - Monosomy 6

KW - Risk stratification

KW - Survival

U2 - 10.1093/neuonc/noq192

DO - 10.1093/neuonc/noq192

M3 - Article

VL - 13

SP - 376

EP - 383

JO - Neuro-Oncology

T2 - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 4

ER -